Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 34Paraganglioma 6Meningioma 6Gastro-enteropancreatic neuroendocrine tumor 6Pheochromocytoma 5Carcinoma, Neuroendocrine 4Neuroblastoma 3Carcinoid Tumor 3Adenoma, Islet Cell 3Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Merkel Cell 2Carcinoma, Medullary 2Somatostatinoma 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Extensive Stage Small Cell Lung Cancer 1

Interventions

Cinacalcet 3belinostat 2Trastuzumab 2Nivolumab 2Denosumab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1fluorodopa F 18 1fluorocholine 1evocalcet 1entinostat 1acetaminophen, codeine drug combination 1Tramadol 1Tablets 1Standard of Care 1Specimen Handling 1Sodium Chloride 1Ritonavir 1Radiotherapy 1Parathyroidectomy 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Gefitinib 1Fluorouracil 1Dacarbazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Parathyroid Neoplasms × lutetium Lu 177 dotatate × Clear all
NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡